FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4384697377> ?p ?o ?g. }

• W4384697377 endingPage "261" @default.
• W4384697377 startingPage "252" @default.
• W4384697377 abstract "BACKGROUND: The role of antidiabetic drugs in inpatient with COVID-19 and type 2 diabetes mellitus (T2DM) is usually considered in the context of target glycemiа maintaining. Except for insulin therapy sulfonylurea may be used in moderate COVID-19. The use of original gliclazide MR has advantages due to low risk of hypoglycemia and established cardio- and nephroprotective effects. But it is not clear whether the choice of antidiabetic drugs during hospitalization may affect patient’s condition in post-COVID period. AIM: . To assess the 12-month dynamics of carbohydrate metabolism in patients with T2DM after hospitalization for COVID-19 considering the character of hypoglycemic therapy in the hospital and the use of gliclazide MR MATERIALS AND METHODS: A 12-month prospective study was performed; T2DM patients were observed after hospitalization for COVID-19. They received in hospital: 1) original gliclazide MR (Diabeton MR, n=20) and 2) insulin (control group, n=20). Changes in antidiabetic therapy, glycemic control and biochemical tests were assessed at baseline and after 3, 6, 12 months. RESULTS: In the main and control groups the intensification of T2DM therapy was observed: the proportion of patients without hypoglycemic drugs decreased within a year by 3.0 (p = 0.001) and 2.8 (p =0.010) times respectively. Mean HbA1c values,the dynamics of inflammation markers and transaminases in both groups were similar (p>0.05 at all visits). Blood creatinine was at baseline 82.9±18.67 and 120.9±45.52 µmol/l (p=0.010), after 3 months — 88.0±18.77 and 104, 5±17.99 µmol/l (p=0.024), after 6 months — 89.3±12.17 and 97.5±9.03 µmol/l (p=0.072), after 12 months — 86.7±10.50 and 93.9±16.76 µmol/l (p=0.16). According to the data obtained during «3 months» visit, the dose of original gliclazide MR was directly correlated with the improvement in renal function in terms of glomerular filtration rateGFR (R=0,59, р=0,010). In addition, there was a close-to-significance correlation between continued gliclazide MR at visit 3 and improvement in GFR at visit 6 (R=0.31, p=0.076). CONCLUSION: The post-hospital period in patients with COVID-19 and T2DM was characterized by a tendency to hyperglycemia and increased need for hypoglycemic therapy. The use of original gliclazide MR by in patients with moderate COVID-19 and T2DM is appropriate and safe in terms of clinical and metabolic parameters dynamics during long-term post-hospital follow-up. When original gliclazide MR is continued during the post-hospital period its nephroprotective properties may contribute to the process of renal functions normalization which should be confirmed by further research." @default.
• W4384697377 created "2023-07-20" @default.
• W4384697377 creator A5002584523 @default.
• W4384697377 creator A5036002753 @default.
• W4384697377 creator A5046664559 @default.
• W4384697377 creator A5052259732 @default.
• W4384697377 creator A5089375517 @default.
• W4384697377 date "2023-07-14" @default.
• W4384697377 modified "2023-09-27" @default.
• W4384697377 title "Results of a 12-month follow-up of patients with type 2 diabetes mellitus after hospitalization with COVID-19: gliclazide MR use in the hospital and metabolic status at the posthospital stage" @default.
• W4384697377 cites W3018753367 @default.
• W4384697377 cites W3022646285 @default.
• W4384697377 cites W3028617446 @default.
• W4384697377 cites W3033938621 @default.
• W4384697377 cites W3036942428 @default.
• W4384697377 cites W3037713006 @default.
• W4384697377 cites W3039938841 @default.
• W4384697377 cites W3046759241 @default.
• W4384697377 cites W3047572188 @default.
• W4384697377 cites W3129777325 @default.
• W4384697377 cites W3134678523 @default.
• W4384697377 cites W3194271815 @default.
• W4384697377 cites W3213801089 @default.
• W4384697377 cites W4206693588 @default.
• W4384697377 cites W4211089661 @default.
• W4384697377 cites W4220791391 @default.
• W4384697377 cites W4225828131 @default.
• W4384697377 cites W4283762359 @default.
• W4384697377 cites W4291465631 @default.
• W4384697377 cites W4294163402 @default.
• W4384697377 cites W4302287640 @default.
• W4384697377 cites W4303634021 @default.
• W4384697377 doi "https://doi.org/10.14341/dm13003" @default.
• W4384697377 hasPublicationYear "2023" @default.
• W4384697377 type Work @default.
• W4384697377 citedByCount "0" @default.
• W4384697377 crossrefType "journal-article" @default.
• W4384697377 hasAuthorship W4384697377A5002584523 @default.
• W4384697377 hasAuthorship W4384697377A5036002753 @default.
• W4384697377 hasAuthorship W4384697377A5046664559 @default.
• W4384697377 hasAuthorship W4384697377A5052259732 @default.
• W4384697377 hasAuthorship W4384697377A5089375517 @default.
• W4384697377 hasBestOaLocation W43846973771 @default.
• W4384697377 hasConcept C126322002 @default.
• W4384697377 hasConcept C134018914 @default.
• W4384697377 hasConcept C151730666 @default.
• W4384697377 hasConcept C2777448766 @default.
• W4384697377 hasConcept C2778854520 @default.
• W4384697377 hasConcept C2779134260 @default.
• W4384697377 hasConcept C2779306644 @default.
• W4384697377 hasConcept C2779343474 @default.
• W4384697377 hasConcept C2780473172 @default.
• W4384697377 hasConcept C2780668416 @default.
• W4384697377 hasConcept C2910068830 @default.
• W4384697377 hasConcept C3008058167 @default.
• W4384697377 hasConcept C524204448 @default.
• W4384697377 hasConcept C555293320 @default.
• W4384697377 hasConcept C70818257 @default.
• W4384697377 hasConcept C71924100 @default.
• W4384697377 hasConcept C86803240 @default.
• W4384697377 hasConcept C90924648 @default.
• W4384697377 hasConceptScore W4384697377C126322002 @default.
• W4384697377 hasConceptScore W4384697377C134018914 @default.
• W4384697377 hasConceptScore W4384697377C151730666 @default.
• W4384697377 hasConceptScore W4384697377C2777448766 @default.
• W4384697377 hasConceptScore W4384697377C2778854520 @default.
• W4384697377 hasConceptScore W4384697377C2779134260 @default.
• W4384697377 hasConceptScore W4384697377C2779306644 @default.
• W4384697377 hasConceptScore W4384697377C2779343474 @default.
• W4384697377 hasConceptScore W4384697377C2780473172 @default.
• W4384697377 hasConceptScore W4384697377C2780668416 @default.
• W4384697377 hasConceptScore W4384697377C2910068830 @default.
• W4384697377 hasConceptScore W4384697377C3008058167 @default.
• W4384697377 hasConceptScore W4384697377C524204448 @default.
• W4384697377 hasConceptScore W4384697377C555293320 @default.
• W4384697377 hasConceptScore W4384697377C70818257 @default.
• W4384697377 hasConceptScore W4384697377C71924100 @default.
• W4384697377 hasConceptScore W4384697377C86803240 @default.
• W4384697377 hasConceptScore W4384697377C90924648 @default.
• W4384697377 hasIssue "3" @default.
• W4384697377 hasLocation W43846973771 @default.
• W4384697377 hasOpenAccess W4384697377 @default.
• W4384697377 hasPrimaryLocation W43846973771 @default.
• W4384697377 hasRelatedWork W1977941268 @default.
• W4384697377 hasRelatedWork W1996441843 @default.
• W4384697377 hasRelatedWork W2011649507 @default.
• W4384697377 hasRelatedWork W2028520749 @default.
• W4384697377 hasRelatedWork W2044021074 @default.
• W4384697377 hasRelatedWork W2052541520 @default.
• W4384697377 hasRelatedWork W2510681507 @default.
• W4384697377 hasRelatedWork W2585489026 @default.
• W4384697377 hasRelatedWork W2615893259 @default.
• W4384697377 hasRelatedWork W3027915394 @default.
• W4384697377 hasVolume "26" @default.
• W4384697377 isParatext "false" @default.
• W4384697377 isRetracted "false" @default.
• W4384697377 workType "article" @default.